An object of the invention is to provide a vaccine adjuvant that is comprised of a vector capable of expressing a polynucleotide binding protein in excess of levels already present in cells. Expression of the polynucleotide binding protein initiates intracellular pathways that lead to expression of type 1 interferons. In concert with expression of type 1 interferons, other cytokines are expressed, and the immune response to vaccine antigens given with the adjuvant is enhanced.
